Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.

Core Insights - BioArctic AB's partner Eisai has launched lecanemab-irmb (Leqembi Iqlik) as a subcutaneous injection for maintenance treatment of Alzheimer's disease in the U.S. after an initial 18-month intravenous treatment [1][7] - Leqembi is the first anti-amyloid treatment that allows at-home injections, enhancing patient convenience and potentially reducing healthcare resource utilization [3][7] - The Leqembi Companion program has been introduced to support patients throughout their treatment journey, providing resources for insurance, financial support, and injection education [1][2] Company Overview - BioArctic AB is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including Alzheimer's disease [10] - The company has a long-standing collaboration with Eisai, which is responsible for the clinical development and commercialization of Leqembi globally [4][9] - BioArctic retains commercialization rights for Leqembi in the Nordic region and has no development costs associated with the drug [9] Product Details - Lecanemab targets both amyloid plaque and protofibrils, which are implicated in the neurodegeneration process of Alzheimer's disease [2][6] - The treatment is approved in 50 countries, including the U.S., Japan, China, and the EU, with ongoing regulatory reviews in 8 additional countries [7] - The Leqembi Iqlik device allows patients to self-administer the treatment at home, which may streamline the overall treatment pathway for Alzheimer's disease [3][7] Clinical Studies - Eisai's Phase 3 clinical study (AHEAD 3-45) is ongoing, focusing on individuals with preclinical Alzheimer's disease, and aims to further evaluate the efficacy of lecanemab [8] - The Tau NexGen clinical study for Dominantly Inherited Alzheimer's Disease (DIAD) is also ongoing, incorporating lecanemab as a key treatment component [8]